GlassScriptPhysician profile
Heather Tyer
NPI 1902144629
$2,488.34
in general payments reported to CMS, 2019-2025
19 companies · $693 in 2025
The $693 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $92.59 · 2023: $386 · 2024: $1,134 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $259.63 | 2024-2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $220.19 | 2024-2025 | Fasenra, Breztri |
| Lilly USA, LLC | $197.55 | 2021-2023 | Mounjaro |
| Amgen INC. | $141.90 | 2023 | Repatha |
| Abiomed | $141.54 | 2024 | Impella |
| Boston Scientific Corporation | $129.60 | 2025 | Watchman Flx |
| Atricure, INC. | $128.66 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2024 | Xifaxan |
| Eisai INC. | $123.81 | 2025 | |
| Alexion Pharmaceuticals, INC. | $122.90 | 2024 | Ultomiris |
| Horizon Therapeutics Plc | $121.60 | 2023 | Uplizna |
| Phathom Pharmaceuticals, INC. | $119.70 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $115.89 | 2025 | Auvelity |
| Madrigal Pharmaceuticals | $114.32 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $113.48 | 2024 | Epclusa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $111.57 | 2024 | Valtoco |
| Shionogi INC | $92.59 | 2022 | |
| Novo Nordisk INC | $84.82 | 2021 | |
| Abbvie INC. | $23.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Tyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.